Health TrialsbyHealthPanel

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

ConditionsPsoriasisAtopic Dermatitis
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of California, San Francisco

About this trial

This study is being done to test a microdevice, which is a small device designed to test drugs directly on skin conditions like atopic dermatitis (eczema) and psoriasis.

The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. Very small amounts of these medications will be released into the skin (at levels in your body much lower than are typically used). In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. We will also look at how these reactions are connected to genetic information and overall treatment results.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial design

Design model

Single group

Treatments tested in this trial

  • In situ cutaneous microdevice

    Device

    The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. The microdevice will contain a subset of the following: Triamcinolone, 5-fluorouracil, Calcipotriene, Tapinarof, Crisaborole, Tacrolimus, Adalimumab, Etanercept, Certolizumab, Infliximab, Secukinumab, Ixekizumab, Apremilast, Risankizumab, Ustekinumab, Hydroxychloroquine, Methotrexate, Mycophenolate, Azathioprine, Chloroquine, Cyclosporine, Tofacitinib, Deucravacitinib, Dupilumab, Tralokinumab, Guselkumab, Tildrakizumab, Baractinib, Abrocitinib, Upadacitinib, Lebrikizumab, Nemolizumab, Ruxolitinib, Bimekizumab, Roflumilast.

  • Triamcinolone

    Drug

    Triamcinolone

  • 5-Fluorouracil

    Drug

    5-fluorouracil

  • Calcipotriene

    Drug

    Calcipotriene

  • Tapinarof

    Drug

    Tapinarof

  • Crisaborole

    Drug

    Crisaborole

  • Tacrolimus

    Drug

    Tacrolimus

  • Adalimumab

    Drug

    Adalimumab

  • Etanercept

    Drug

    Etanercept

  • Certolizumab

    Drug

    Certolizumab

  • Infliximab

    Drug

    Infliximab

  • Secukinumab

    Drug

    Secukinumab

  • Ixekizumab

    Drug

    Ixekizumab

  • Apremilast

    Drug

    Apremilast

  • Risankizumab

    Drug

    Risankizumab

  • Ustekinumab

    Drug

    Ustekinumab

  • Hydroxychloroquine

    Drug

    Hydroxychloroquine

  • Methotrexate

    Drug

    Methotrexate

  • Mycophenolate

    Drug

    Mycophenolate

  • Azathioprine

    Drug

    Azathioprine

  • Chloroquine

    Drug

    Chloroquine

  • Cyclosporine

    Drug

    Cyclosporine

  • Tofacitinib

    Drug

    Tofacitinib

  • Deucravacitinib

    Drug

    Deucravacitinib

  • Dupilumab

    Drug

    Dupilumab

  • Tralokinumab

    Drug

    Tralokinumab

  • Guselkumab

    Drug

    Guselkumab

  • Tildrakizumab

    Drug

    Tildrakizumab

  • Baractinib

    Drug

    Baractinib

  • Abrocitinib

    Drug

    Abrocitinib

  • Upadacitinib

    Drug

    Upadacitinib

  • Lebrikizumab

    Drug

    Lebrikizumab

  • Nemolizumab

    Drug

    Nemolizumab

  • Ruxolitinib

    Drug

    Ruxolitinib

  • Bimekizumab

    Drug

    Bimekizumab

  • Roflumilast

    Drug

    Roflumilast

Treatment groups

10 Participants
are divided into 1 treatment group
Group A: In situ cutaneous microdeviceExperimental treatment 36 interventions

Trial outcomes

Primary outcomes

1

Number of participants with adverse events

The safety of microdevice placement and removal will be based on assessment of adverse events.

Time frame
1 year
2

Proportion of retrieved devices with assessable tissue

The feasibility of microdevice analysis based on the ability to place and retrieve the device with sufficient tissue, of sufficient quality, for downstream histopathology/molecular analysis and interpretation of at least 80% of the device reservoirs.

Time frame
1 year

Secondary outcomes

1

Change in local skin inflammation (molecular assays)

Feasibility of utilizing quantitative histopathologic assessment and/or transcriptional profiling to determine whether there is local change in lesional rash-affected skin with clinically relevant skin inflammation treating agents.

Time frame
1 year

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of California, San Francisco

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: